<DOC>
	<DOCNO>NCT02192099</DOCNO>
	<brief_summary>Examine safety long term repeat exposure GLYX-13 subject participate GLYX13-C-202 .</brief_summary>
	<brief_title>Open Label Extension GLYX13-C-202 , NCT01684163</brief_title>
	<detailed_description>Examine safety long term repeat exposure GLYX-13 subject participate GLYX13-C-202 open label extension trial .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>1 . Participants complete 8 week treatment precede study ( GLYX13C202 , NCT01684163 . 2 . Participants wish continue treatment GLYX13 preceding study . 3 . Meets Diagnostic Statistical Manual , Fourth Edition , Text Revision ( DSMIVTR ) criteria major depressive disorder ( MDD ) . 4 . Female subject childbearing potential negative serum pregnancy test prior entry study practice adequate method birth control ( eg oral parenteral contraceptive , intrauterine device , barrier , abstinence ) plan become pregnant course study . Female subject may include without negative serum pregnancy test surgically sterile least 2 year postmenopausal . 5 . Clinical laboratory value &lt; 2 time upper limit normal ( ULN ) deem clinically significant per investigator Naurex medical monitor . 6 . Ability understand requirement study , provide write informed consent , abide study restriction , agree return require assessment . 7 . Based investigator Naurex medical monitor 's clinical judgment , subject eat disorder , obsessive compulsive disorder ( OCD ) , panic disorder , posttraumatic stress disorder ( PTSD ) , generalize anxiety disorder secondary major depressive episode ( MDEs ) permit . 1 . Axis I diagnosis delirium , dementia , dysthymia , amnestic cognitive disorder , schizophrenia psychotic disorder , bipolar I II disorder , eat disorder ( anorexia bulimia nervosa ) , obsessivecompulsive disorder , panic disorder , acute stress disorder , agoraphobia , social phobia , attentiondeficit hyperactivity disorder ( ADHD ) , PTSD . 2 . A clinically significant current Axis II diagnosis borderline , antisocial , paranoid , schizoid , schizotypal , histrionic personality disorder 3 . Experiencing hallucination , delusion , psychotic symptomatology current episode ; lifetime history psychosis . 4 . Huntington 's , Parkinson 's , Alzheimer 's , Multiple Sclerosis , history seizure stroke . 5 . Currently hospitalize reside inpatient facility study participation . 6 . Substance abuse since end participation GLYX13C202 , include great equal 5 unit alcohol per day 1 unit = Â½ pint beer , 1 glass wine 4 oz , 1 oz . spirit consume week opinion investigator 7 . Women plan become pregnant course study . 8 . Allergy intolerance current antidepressant current medication . 9 . Participation clinical trial investigational product device within 30 day enrollment trial exception GLYX13C202 . 10 . Positive screen drug abuse : cocaine , marijuana , PCP , ketamine , opioid agent opinion investigator abuse 11 . Pose current ( past 6 month ) suicide risk base administration C SSRS investigator 's clinical judgment . 12 . Human immunodeficiency virus ( HIV ) infection ( base base HIV1 &amp; HIV2 antibody screen ) ongoing infectious disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>